Alexander V. Alfano

I'll research this attorney before writing the summary.

Professional Summary — Alexander V. Alfano

Focus areas (life sciences / Hatch-Waxman). Alfano's patent litigation practice is concentrated in pharmaceuticals rather than electronics or standards-based technologies such as Wi-Fi. Sterne Kessler's own bio describes his focus as patent litigation and counseling in pharmaceuticals, medical devices, and biotechnology, with regular Hatch-Waxman Paragraph IV work, plus FDA regulatory counseling (marketing exclusivity, labeling, patent listing and certification, citizen petitions) and experience before the U.S. International Trade Commission. He holds a B.S. in biology from Quinnipiac University, which is consistent with the life-sciences orientation. Independent evidence corroborates the Hatch-Waxman concentration: Patexia's ANDA Litigation 2025 Intelligence Report placed him in its top 10 for overall ANDA activity and top 10 for plaintiff-side activity, and its 2024 report listed him among the top 50 best-performing ANDA attorneys on the defense side. No software, mechanical, or wireless-standards work is reflected in the tracked record or firm materials.

Side preference — both sides, weighted toward Hatch-Waxman litigation. The single tracked appearance in this dataset is defense-side (Unified Patents, LLC v. Breckenridge Pharmaceutical Inc., with Sterne Kessler listed as counsel), but that one data point materially understates his docket. The Patexia rankings cited above recognize him for both plaintiff and defendant ANDA activity, and court filings show him appearing for both branded/innovator and generic clients — e.g., for plaintiff American Regent, Inc. in the In re Selenious Acid Litigation (D.N.J.) and for Dexcel Pharma as defendant against Pfizer (D. Del.), as well as in consolidated Hatch-Waxman matters in Delaware. He is not an NPE/PAE-side prosecutor; his work is conventional Hatch-Waxman and life-sciences patent litigation.

Firm context. Alfano is at Sterne, Kessler, Goldstein & Fox P.L.L.C. in Washington, D.C., where firm material describes him as an associate in the Trial and Appellate Practice Group (the dataset lists his role as "Counsel"). I found no verified prior firm history; his public profile is associated with Sterne Kessler throughout the period covered by available sources. His Hartnett-Connecticut "Rising Star" recognition in 2021–2022 suggests earlier New England connections, but I could not confirm any prior employer and would not assert one.

Representative matters. The most prominent verifiable results are (1) Sterne Kessler client Dexcel Pharma's resolution of Pfizer's patent litigation over VYNDAMAX® (tafamidis) in D. Del., where the parties agreed to dismiss on April 24, 2026 shortly before a scheduled bench trial — Alfano is named on the firm's matter team; and (2) the In re Selenious Acid Litigation (D.N.J., No. 2:24-cv-07791), where he was admitted pro hac vice for plaintiff American Regent, Inc. in its consolidated action against Accord Healthcare and others. He is also named on filings in consolidated Hatch-Waxman litigation in the District of Delaware. I did not verify any trial verdict, Federal Circuit opinion, or damages award attributable to him individually; the outcomes above are settlements and litigation representation, not adjudicated wins.

PTAB / IPR experience. His PTAB activity is real but modest on the public record. The tracked matter — Unified Patents, LLC v. Breckenridge Pharmaceutical Inc. — appears to be a Board proceeding in which Breckenridge was the patent owner/defendant side, and Sterne Kessler's bio states he has experience representing clients before the Patent Trial and Appeal Board. I would characterize this as occasional PTAB work rather than a practice built around IPR/PGR petitions. (Caution: I could not independently confirm his individual appearance papers in that specific PTAB matter beyond the tracked listing.)

Bar and education. J.D., Fordham University School of Law (2015); B.S., Biology, Quinnipiac University; registered to practice before the USPTO (Reg. No. 74298). Admitted in Connecticut, New York, and the District of Columbia, and before the U.S. District Court for the District of Connecticut; filings describe him as an associate appearing pro hac vice in New Jersey. One third-party directory (Super Lawyers) lists D.C. licensure as dating to 2000, which is inconsistent with a 2015 J.D. and appears to be a data error; Sterne Kessler's 2024 Best Lawyers release separately noted he was then admitted only in New York and Connecticut and practicing under D.C. Bar supervision.

Sourcing note: the case list supplied is authoritative for tracked appearances and contains only one matter; the broader picture above rests on Sterne Kessler's website and press releases, Patexia rankings as reported by the firm, Best Lawyers/Super Lawyers listings, and federal court filings via CourtListener and archive.org. No non-legal or personal sources were used.